Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice

Journal of Immunology

Volumn 165, Issue 11, 2000, Pages 6024-6028

  Kacha, A K ^a   Fallarino, F ^a   Markiewicz, M A ^a   Gajewski, T F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 4; STAT6 PROTEIN; TUMOR ANTIGEN; DNA BINDING PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; STAT1 PROTEIN; STAT1 PROTEIN, MOUSE; STAT6 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REJECTION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIFFERENTIATION; COMPARATIVE STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DBA MOUSE; GENETIC TRANSFECTION; GENETICS; GRAFT REJECTION; IMMUNOLOGY; LEUKEMIA L 1210; METABOLISM; MOUSE MUTANT; SARCOMA; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, NEOPLASM; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DNA-BINDING PROTEINS; GRAFT REJECTION; INTERFERON TYPE II; INTERLEUKIN-12; LEUKEMIA L1210; MAST-CELL SARCOMA; MICE; MICE, INBRED DBA; MICE, KNOCKOUT; NEOPLASM TRANSPLANTATION; STAT1 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0034545618     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.11.6024     Document Type: Article

References (30)

1. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response
2. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells
3. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12
4. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
5. Sequential development of structural and functional alterations in T cells from tumor-bearing mice
6. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
7. + T cell- and IL-2-dependent mechanism
8. + T lymphocytes in peripheral blood of patients with advanced melanoma
9. Inhibition of tumor growth by elimination of granulocytes
10. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells
11. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo
12. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
13. Cutting edge: Differentiation of antitumor CTL in vivo requires host expression of Stat1
14. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
15. + T cells from T cell receptor transgenic mice
16. Requirement for IL-13 independently of IL-4 in experimental asthma
17. IL-13, IL-4Rα, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis
18. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent
19. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor
20. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors
21. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells
22. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice
23. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis
24. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are protected from antigen-induced airway hyperresponsiveness and mucus production
25. Signal transducer and activator of transcription 6 is essential in the induction of contact hypersensitivity
26. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease
27. Selection of highly transfectable variant from mouse mastocytoma P815
28. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: Superiority of B7-1 over B7-2 for active tumor immunization
29. Interleukin-4 and interleukin-13: Their similarities and discrepancies
30. + T cells in the antitumor immune response